Keywords: Vertex, VX-809, Kalydeco, Ph II final data, Cystic fibrosis

Vertex tumbles despite good final data on combo cystic fibrosis therapy

Article | 01 July 2012

Print This

USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares tumble 16% to $51.18 last week, after the company announced final data from a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in